Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Our Science

> Our Science

> Poster and Presentation

Poster and Presentation

Peer Reviewed Publications

Poster and Presentation

2016 ADA Poster

Clinical Proof of Concept (POC) of Glucokinase Activator HMS5552 Achieved in Chinese T2DM Patients: HbA1c Reduction of 1.22% with 100% Response Rate and Improved β-cell Function

2016 Chinese Pharmacological Society

Prediction of HMS5552 human pharmacokinetics using Allometric Scaling, IVIVE,Css-MRT and PBPK Modeling Methods （2016 中國(guó)藥理學(xué)會(huì)定量藥理學(xué)專(zhuān)業(yè)委員會(huì)年會(huì)）

2015 ADA Poster

Clinically Differentiated Glucokinase Activator HMS5552: Effective Control of 24-Hour Glucose and Improvement of β Cell Function in T2DM Patients

2015 ADA Poster

A Novel Dual Pancreatic and Hepatic Acting Glucokinase Activator, HMS5552: Phase I Studies in Healthy Subjects and T2DM Patients

2015 February/ Intractable & Rare Diseases Research

Fragile X syndrome as a rare disease in China - Therapeutic challenges and opportunities.

2015 CDS

葡萄糖激酶激活劑HMS5552對(duì)2型糖尿病大鼠肝組織中葡萄糖激酶的調(diào)節(jié)作用（2015 CDS）

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(華堂寧®)

Focus Us

滬公網(wǎng)安備 31011502013809號(hào) Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.

Our Science

Poster and Presentation

Clinical Proof of Concept (POC) of Glucokinase Activator HMS5552 Achieved in Chinese T2DM Patients: HbA1c Reduction of 1.22% with 100% Response Rate and Improved β-cell Function

Prediction of HMS5552 human pharmacokinetics using Allometric Scaling, IVIVE,Css-MRT and PBPK Modeling Methods （2016 中國(guó)藥理學(xué)會(huì)定量藥理學(xué)專(zhuān)業(yè)委員會(huì)年會(huì)）

Clinically Differentiated Glucokinase Activator HMS5552: Effective Control of 24-Hour Glucose and Improvement of β Cell Function in T2DM Patients

A Novel Dual Pancreatic and Hepatic Acting Glucokinase Activator, HMS5552: Phase I Studies in Healthy Subjects and T2DM Patients

Fragile X syndrome as a rare disease in China - Therapeutic challenges and opportunities.

葡萄糖激酶激活劑HMS5552對(duì)2型糖尿病大鼠肝組織中葡萄糖激酶的調(diào)節(jié)作用 （2015 CDS）

葡萄糖激酶激活劑HMS5552對(duì)2型糖尿病大鼠肝組織中葡萄糖激酶的調(diào)節(jié)作用（2015 CDS）